Cardiac Resynchronization Therapy Devices Market: Market Size & Forecast 2026

Cardiac resynchronization therapy devices are implantable systems designed to correct electrical dyssynchrony in heart failure patients, improving cardiac efficiency and reducing symptoms. The global market, valued at approximately $5.8 billion in 2025, is projected to grow steadily as clinical evidence continues to demonstrate the cost-effectiveness of device-based interventions in managing heart failure. As the economic burden of heart failure escalates, with U.S. costs alone projected to reach $70 billion by 2030, CRT devices represent a significant and expanding segment of the cardiovascular device industry.

• •CRT devices include CRT-D (defibrillator) and CRT-P (pacemaker) systems for eligible heart failure patients
• •Heart failure economic costs in the U.S. are projected to reach $70 billion by 2030
• •CRT remains essential for patients experiencing incomplete response to medical therapy alone

The primary driver of market growth is the rising global burden of heart failure, fueled by aging demographics and increasing prevalence of comorbidities such as hypertension, diabetes, and coronary artery disease. Advances in device technology, including longer battery life, improved leads, and miniaturized systems, are expanding the eligible patient population and encouraging earlier adoption of CRT therapy. Cost-effectiveness analyses have demonstrated that CRT interventions can reduce long-term hospitalizations, making them increasingly favorable to healthcare payers and providers operating under value-based care models.

• •Real-world observational data on nearly 65,000 patients showed steady improvements in 1-year survival and reduced hospitalizations over a decade
• •Guideline-directed medical therapy combined with device interventions is being evaluated for cost-effectiveness across healthcare systems
• •Remote monitoring integration into CRT devices supports more proactive patient management and reduced healthcare utilization

The market is broadly segmented by device type, with CRT-D devices accounting for a larger share due to their dual function of resynchronization therapy and defibrillation, while CRT-P devices serve patients who do not require defibrillation capabilities. Regional adoption varies significantly, with European markets showing mature implantation rates, ESC member countries report a median of 54 CRT-D implantations per million people, while emerging markets in Asia-Pacific and Latin America are experiencing accelerated growth due to improving healthcare infrastructure and rising disease awareness. Disparities in device access remain a concern, with research highlighting equity gaps in the adoption of advanced heart failure technologies across different patient populations and geographic regions.

• •Median CRT-D implantation rates across ESC member countries stand at approximately 54 per million population
• •Access to CRT devices varies across regions, with equity gaps documented in adoption rates for advanced heart failure technologies
• •Emerging markets are driving growth as healthcare infrastructure and disease awareness improve

What are the recent trends and outlook?

The integration of remote monitoring and telehealth capabilities into CRT devices is emerging as a defining trend, enabling clinicians to track device performance and patient status between in-person visits and potentially reducing hospitalization rates. Ongoing research is focused on improving patient selection criteria to maximize the therapeutic benefit of CRT, as a subset of patients remains non-responsive to therapy. The future outlook includes continued technological refinements, efforts to expand access in underserved regions, and growing emphasis on health economics research to further validate the long-term value proposition of CRT interventions within healthcare systems worldwide.

• •Remote monitoring algorithms integrated into CRT devices support more proactive heart failure management and improved health equity outcomes
• •Research priorities include optimizing patient selection and addressing clinical gaps to maximize therapeutic response
• •Regulatory harmonization efforts may facilitate smoother global market access for next-generation CRT devices through 2030